Combining Serum PVT1 Exon 4A and Exon 9 with Serum Prostate-Specific Antigen Shows Potential for Improving Identification and Risk Stratification of Prostate Cancer
Emmanuel Asante-Asamani, Rachel E Bonacci, Tinovimba Hove, S H Dinuka Sewwandi de Silva, Michael A Liss, Robin Leach, Olorunseun O Ogunwobi · 2026
Read Combining Serum PVT1 Exon 4A and Exon 9 with Serum Prostate-Specific Antigen Shows Potential for Improving Identification and Risk Stratification of Prostate Cancer by Emmanuel Asante-Asamani, Rachel E Bonacci, Tinovimba Hove, S H Dinuka Sewwandi de Silva, Michael A Liss, Robin Leach, Olorunseun O Ogunwobi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13310659.txt.
Description
Emmanuel Asante-Asamani and co-authors test blood RNA markers to sharpen prostate cancer detection in a 2026 study. The standard PSA blood test flags many harmless cases and was weakly validated in men of African ancestry, who bear the highest disease burden. RNA pieces from the PVT1 gene run high in prostate tumors and may add signal.
Serum from 144 men with raised PSA who faced biopsy was tested for three PVT1 segments, alone and joined with PSA. Statistical models weighed added detection value and risk sorting, with cross-checks for overfitting. The study is the first serum test of these segments in this setting. The authors frame combined markers as a route to fewer needless biopsies, above all in high-burden groups.
Catalog record
| CREATOR | Emmanuel Asante-Asamani, Rachel E Bonacci, Tinovimba Hove, S H Dinuka Sewwandi de Silva, Michael A Liss, Robin Leach, Olorunseun O Ogunwobi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70373 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |